[1] Campochiaro, P.A. (2012) Anti-Vascular Endothelial Growth Factor Treatment for Retinal Vein Occlusions. Ophthalmologica, 227, 30-35.
http://dx.doi.org/10.1159/000337157
[2] Spaide, R.F., Chang, L.K., Klancnik, J.M., Yannuzzi, L.A., Sorenson, J., Slakter, J.S., et al. (2009) Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion. American Journal of Ophthalmology, 147, 298-306. http://dx.doi.org/10.1016/j.ajo.2008.08.016
[3] Pieramici, D.J., Rabena, M., Castellarin, A.A., Nasir, M., See, R., Norton, T., et al. (2008) Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein Occlusions. Ophthalmology, 115, 47-54.
http://dx.doi.org/10.1016/j.ophtha.2008.06.021
[4] Antonetti, D.A., Barber, A.J., Khin, S., Lieth, E., Tarbell, J.M. and Garnder, T.W. (1998) Vascular Permeability in Experiment Diabetes Is Associated with Reduced Endothelial Occludin Content: Vascular Endothelial Growth Factor Decreases Occludin in Retinal Endothelial Cells. Penn State Retina Research Group. Diabetes, 47, 1953-1959.
http://dx.doi.org/10.2337/diabetes.47.12.1953
[5] Rehak, J. and Rehak, M. (2008) Branch Retinal Vein Occlusion: Pathogenesis, Visual Prognosis, and Treatment Modalities. Current Eye Research, 33, 111-131.
http://dx.doi.org/10.1080/02713680701851902
[6] Lu, B.W. and Wu, X.W. (2013) Clinical Study on Traditional Chinese Medicine in the Treatment of Patients with Macular Edema Secondary to Retinal Vein Occlusion. China Journal of Chinese Ophthalmology, 23, 328-333.
[7] Hahn, P. and Fekrat, S. (2012) Best Practices for Treatment of Retinal Vein Occlusion. Current Opinion in Ophthalmology, 23, 175-181.
http://dx.doi.org/10.1097/ICU.0b013e3283524148
[8] Feng, Y.L. and Wu, XW. (2015) Ranibizumab Combined with Compound Salvia in Treating Macular Edema Secondary to Branch Retinal Vein Occlusion. Chinese Journal of Ocular Fundus Diseases, 25, 107-110.
[9] Chatziralli, I.P., Jaulim, A., Peponis, V.G., Mitropoulos, P.G. and Moschos, M.M. (2014) Branch Retunal Vein Occlusion: Treatment Modalities: An Update of the Literature. Seminars in Ophthalmology, 29, 85-107.
http://dx.doi.org/10.3109/08820538.2013.833271
[10] Noma, H., Funatsu, H., Yamasaki, M., Tsukamoto, H., Mimura, T., Sone, T., et al. (2008) Aqueous Humour Levels of Cytokines Are Correlated to Vitreous Levels and Severity of Macular Oedema in Branch Retinal Vein Occlusion. Eye, 22, 42-48.
http://dx.doi.org/10.1038/sj.eye.6702498
[11] Blick, S.K., Keating, G.M. and Wagstaff, A.J. (2007) Ranibizumab. Drugs, 67, 1199-1206.
http://dx.doi.org/10.2165/00003495-200767080-00007
[12] Ferrara, N., Damico, L., Shams, N., Lowman, H. and Kim, R. (2006) Development of Ranibizumab, an Anti-Vascular Endothelial Growth Factor Antigen Binding Fragment, as Therapy for Neovascular Age-Related Macular Degeneration. Retina, 26, 859-870.
http://dx.doi.org/10.1097/01.iae.0000242842.14624.e7
[13] Ferrara, N. (2010) Vascular Endothelial Growth Factor and Age-Related Macular Degeneration: From Basic Science to Therapy. Nature Medicine, 16, 1107-1111.
http://dx.doi.org/10.1038/nm1010-1107
[14] Brown, D.M., Campochiaro, P.A., Bhisitkul, R.B., Ho, A.C., Gray, S., Saroj, N., et al. (2011) Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study. Ophthalmology, 118, 1594-1602.
http://dx.doi.org/10.1016/j.ophtha.2011.02.022
[15] Tan, M.H., Mcallister, I.L., Gillies, M.E., Verma, N., Banerjee, G., Smithies, L.A., Wong, W.-L. and Wong, T.Y. (2014) Randomized Controlled Trial of Intravitreal Ranibizumab versus Standard Grid Laser for Macular Edema Following Branch Retinal Vein Occlusion. American Journal of Ophthalmology, 157, 237-247.
http://dx.doi.org/10.1016/j.ajo.2013.08.013
[16] Gallego-Pinazo, R., Dolz-Marco, R., Pardo-López, D., Martínez-Castillo, S., Lleó-Pérez, A., Arévalo, J.F. and Díaz-Llopis, M. (2013) Ranibizumab for Serous Macular Detachment in Branch Retinal Vein Occlusions. Graefe’s Archive for Clinical and Experimental Ophthalmology, 251, 9-14. http://dx.doi.org/10.1007/s00417-012-2023-7
[17] Lu, B.W. and Wu, X.W. (2013) Recent Advances in Therapy for Macular Edema Secondary to Retinal Vein Occlusion. Chinese Journal of Ocular Fundus Diseases, 29, 640-644.
[18] Wang, Z.C. (2006) The Discussion of the Efficacy and Adversereaction of Salvia Injection. Chinese Medical Journal, 4, 545-546.
[19] Pan, L.X. (2003) Low Molecular Dextran Combine with Compound Salvia in the Treatment of BRVO. Journal of Practical Medical Techniques, 10, 1026-1027.
[20] Zhang, X.Y., Li, Y.B., Zhou, L.W., Wang, X.B. and Luo, X.D. (2014) Ranibizumab Combined with Grid Laser in the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion. International Journal of Ophthalmology, 14, 47-49.
[21] Zhang, H., Liu, Y.-Y., Jiang, Q., Li, K.-R., Zhao, Y.-X., Cao, C. and Yao, J. (2014) Salvianolic Acid A Protects RPE Cells against Oxidative Stress through Activation of Nrf2/HO-1 Signaling. Free Radical Biology and Medicine, 69, 219-228.
http://dx.doi.org/10.1016/j.freeradbiomed.2014.01.025
[22] Xu, G.X., Peng, Y.H. and Yue, Z.Z. (2006) Observation on Therapeutic Effects of Diabetes with Peripheral Nervus Disease Treated with compound salvia and mecobalamin. Chinese Journal of Rural Medicine and Pharmacy, 13, 18-19.